Burn-Care AI Seeks $2,750 Medicare Add-On Payment
Hospitals weighing DeepView AI systems would receive added per-patient reimbursement if CMS approves the pending NTAP application.
Updated on Nov. 21, 2026 in Healthcare

Spectral AI reported progress in shifting from a research organization toward a commercial medical technology company, including beginning manufacture of its first 30 DeepView AI systems for BARDA-supported deployments at US burn centers. Its commercial agreements carry a minimum three-year term and pair device purchases or leases with recurring software and service revenue.
Why it matters
The move from government-funded research toward commercial software revenue is intended to build long-term margins, a pattern operators in medical technology and healthcare services will recognize as a shift from one-time contract work to recurring subscription income. The company also submitted an NTAP application to CMS, which would determine whether hospitals receive added Medicare reimbursement for the technology.
Spectral AI began manufacturing 30 initial DeepView AI systems and proposed a $2,750-per-patient Medicare add-on through an NTAP application, with commercial agreements carrying a minimum three-year term. The company has not yet received a determination on the NTAP request, and the earnings disclosures did not establish a margin comparison against its prior research-funded revenue.
The players
Spectral AI
A medical technology company developing AI-driven diagnostic imaging for burn care, now moving from government-funded research toward commercial software and device sales.
Centers for Medicare and Medicaid Services
The federal agency that administers Medicare and sets hospital reimbursement rules, including the New Technology Add-on Payment program that would apply to the DeepView system.
The details
Spectral AI's commercial agreements pair device purchases or leases with recurring software and service fees, so the company earns ongoing revenue as its installed base grows rather than a single payment per deployment. Its NTAP application to the Centers for Medicare and Medicaid Services would give hospitals an additional $2,750 per patient in Medicare reimbursement if approved, which would affect whether hospitals can justify adopting the system. Management expects commercial sales to deliver higher margins than development work as the installed base expands. Routine burn care is the main commercial target beyond mass-casualty preparedness.
Timeline
Early in Q3 2026: Spectral AI submitted its NTAP application to CMS.
Q3 2026: The company began manufacturing its first 30 DeepView AI systems.
November 10, 2026: Spectral AI held its third-quarter 2026 earnings call.
2026: Commercial sales of DeepView are targeted to begin.
Market Landscape
Spectral AI's application to the NTAP program follows the standard route medical device makers use to secure added Medicare payment for new technologies. The shift toward recurring software revenue reflects a broader move among medical technology companies away from one-time government development contracts.
Hospital finance and procurement teams should track whether CMS grants the NTAP add-on, since it would change the reimbursement math for adopting DeepView. Operators in healthcare equipment supply should watch for the recurring-subscription pricing model, which shifts cost from upfront capital to multi-year commitments.
The takeaway
Commercial medical technology sellers are moving toward multi-year software and service contracts, which changes both cash flow and purchasing decisions for hospitals. Track the outcome of the NTAP application, since its approval or denial will largely determine hospital adoption economics.
Further reading
For more on how medical device companies bring new technology to hospitals, see United States Healthcare.
Source note: This article includes information reported by The Motley Fool.





